Fig. 4

STIM1 and ORAI1 regulate proliferation of thyroid cancer ML-1 cells. A STIM1 and ORAI1 knock-down decreased proliferation after 48 h. The bar diagram shows the mean ± S.E. (n = 3). ***p < 0.001. B, C STIM1 and ORAI1 knock-down decreased proliferation by prolonging the G₁ phase and decreasing the S phases of the cell cycle. ***p < 0.001. *Statistically significant differences between the G₁ and S phases of cell cycle, respectively, in STIM1-KD and ORAI1-KD cells compared with the MOCK cells. D, Representative Western blots showing the upregulation of p21 and p27 in both STIM1 and ORAI1-KD cells. E Representative Western blot showing the downregulation of cyclin-dependent kinase 6 (cdk6) in both STIM1 and ORAI1-KD cells. F–H Cells were treated with indicated concentrations of Lenvatinib, Paclitaxel or Doxorubicin and the proliferation was assessed by MTT proliferation assays (24 h. The effects of tested drugs were significant (p < 0.001) in STIM1-KD compared with MOCK cells. Each data point represents the mean ± S.E. of at least three independent experiments